Saturday, 17 October 2026European Markets

METABOLIC EXPLORER Stock Over 34% Down In The Last 21 Sessions

Loading stream...

metabolic explorer (metex.pa), a biological chemistry firm listed on france's cac 40 index, experienced an unexpected 34.45% share price drop over 21 sessions from eur1.19 to eur0.78, experiencing five straight loss sessions en route. despite an overall cac 40 index increase to eur7,240.88 this happened despite this dip.

stock performance overview

metabolic explorer's precipitous price decline puts it significantly below its 52-week peak of eur2.78. metabolic explorer closed last session trading at eur0.76, representing an incredible 72.64% drop from its 52-week high of eur2.78.

about metabolic explorer

metabolic explorer specializes in industrial fermentation processes as a greener alternative to petrochemical processes, offering its products globally from propanediol and butyric acid, glycolic acid, l-valine and more - used in products as diverse as cosmetics, textiles, polymers and animal nutrition as well as serving as foundation materials for biomaterial synthesis. established in 1999 and headquartered in saint-beauzire france since then; however, profitability issues persist at this company that was founded 17 years ago.

financial performance

metabolic explorer's earnings per share for the trailing twelve months was an alarming eur-1.13; furthermore, its return on equity--an indicator of how well a company generates profits using shareholders' equity--was at an alarming negative -39.56%, reflecting an alarming downward trend. these numbers demonstrate its financial hardships while seemingly reflecting in its stock prices as they drop further and further away.

more news about metabolic explorer (metex.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com